See What HealthDay Can Do For You
Contact Us

More Reassurance Against MMR-Autism Link

Finding held true even for children at risk for the developmental disorder

WEDNESDAY, April 22, 2015 (HealthDay News) -- Yet another study finds no evidence that the measles-mumps-rubella (MMR) vaccine raises the risk of autism -- even among children who are at increased genetic risk. The latest research was reported in the April 21 issue of the Journal of the American Medical Association, a theme issue on child health.

The new findings are based on insurance records for 95,727 U.S. children with an older brother or sister; 2 percent had an older sibling with an autism spectrum disorder.

The researchers found that of the children with an affected sibling, 6.9 percent had an autism spectrum disorder themselves, compared to 0.9 percent of other children. There was no evidence, though, that the MMR vaccination raised the risk of autism in either group of children. Among children with an affected sibling, those who'd received one MMR dose by age 2 were actually one-quarter less likely to be diagnosed with an autism spectrum disorder. The odds were even lower among those who'd received two doses by age 5.

"Research has shown that parents of kids with autism spectrum disorders are more likely to delay vaccinating their younger children," Bryan King, M.D., an autism researcher at the University of Washington in Seattle, told HealthDay. "Basically, they wait until the developmental dust has settled, and it looks like their child will be unaffected," he said. King wrote an editorial published with the study.

Abstract
Full Text
Editorial (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.